| Code | CSB-RA015007MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to rituximab, targeting MS4A1 (Membrane Spanning 4-Domains A1), more commonly known as CD20. CD20 is a transmembrane phosphoprotein exclusively expressed on the surface of B cells from the pre-B cell stage through mature B lymphocytes, but absent on plasma cells. This antigen plays a critical role in B cell activation, proliferation, and differentiation through regulation of calcium influx and cell cycle progression. CD20 expression is maintained on malignant B cells in various hematologic cancers and is also implicated in autoimmune diseases where aberrant B cell activity drives pathology.
Rituximab, the reference antibody, was the first monoclonal antibody approved for cancer therapy and remains a cornerstone therapeutic for B cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, and autoimmune conditions including rheumatoid arthritis and pemphigus vulgaris. This biosimilar provides researchers with a validated tool for investigating B cell depletion mechanisms, studying CD20-mediated signaling pathways, evaluating antibody-dependent cellular cytotoxicity, and developing novel therapeutic strategies targeting B cell-mediated disorders.
There are currently no reviews for this product.